Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (139) 139
male (118) 118
female (115) 115
middle aged (102) 102
aged (90) 90
cardiac & cardiovascular systems (66) 66
index medicus (65) 65
risk factors (48) 48
drug therapy (43) 43
medicine, general & internal (43) 43
stroke (43) 43
double-blind method (40) 40
adult (39) 39
mortality (39) 39
treatment outcome (39) 39
risk (36) 36
abridged index medicus (35) 35
cardiovascular disease (34) 34
myocardial infarction (34) 34
prevention (34) 34
atrial fibrillation (30) 30
medicin och hälsovetenskap (29) 29
medical and health sciences (28) 28
cardiovascular diseases (27) 27
drug therapy, combination (26) 26
aspirin (24) 24
care and treatment (24) 24
follow-up studies (24) 24
heart attacks (23) 23
hemorrhage - chemically induced (23) 23
platelet aggregation inhibitors - therapeutic use (23) 23
therapy (23) 23
cardiovascular diseases - prevention & control (21) 21
electrocardiography (20) 20
atrial fibrillation - drug therapy (19) 19
incidence (19) 19
warfarin (19) 19
diabetes (18) 18
hypertension (18) 18
myocardial-infarction (18) 18
peripheral vascular disease (18) 18
acute coronary syndromes (17) 17
anticoagulants (17) 17
clinical trials (17) 17
ticlopidine - analogs & derivatives (17) 17
anticoagulants - therapeutic use (16) 16
cardiovascular diseases - mortality (16) 16
clopidogrel (16) 16
management (16) 16
myocardial infarction - drug therapy (16) 16
platelet aggregation inhibitors - adverse effects (16) 16
stroke - prevention & control (16) 16
ticlopidine - therapeutic use (16) 16
myocardial infarction - mortality (15) 15
patient outcomes (15) 15
research (15) 15
time factors (15) 15
blood pressure (14) 14
cerebral infarction (14) 14
diabetes mellitus (14) 14
health risk assessment (14) 14
heart diseases (14) 14
hemorrhage (14) 14
prospective studies (14) 14
unstable angina (14) 14
acute myocardial-infarction (13) 13
dosage and administration (13) 13
events (13) 13
health aspects (13) 13
patients (13) 13
fibrinolytic agents - therapeutic use (12) 12
medicine (12) 12
metaanalysis (12) 12
outcomes (12) 12
usage (12) 12
acute coronary syndrome - drug therapy (11) 11
aged, 80 and over (11) 11
anticoagulation (11) 11
aspirin - therapeutic use (11) 11
coronary heart disease (11) 11
kaplan-meier estimate (11) 11
myocardial infarction - complications (11) 11
proportional hazards models (11) 11
registries (11) 11
thromboembolism (11) 11
anticoagulants - adverse effects (10) 10
cardiovascular diseases - epidemiology (10) 10
cholesterol (10) 10
clinical medicine (10) 10
complications and side effects (10) 10
coronary angiography (10) 10
coronary artery bypass (10) 10
coronary artery disease (10) 10
death (10) 10
medical research (10) 10
myocardial infarction - epidemiology (10) 10
prevalence (10) 10
ticlopidine - adverse effects (10) 10
acute disease (9) 9
antithrombotic therapy (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by Yusuf, Salim and Bosch, Jackie and Dagenais, Gilles and Zhu, Jun and Xavier, Denis and Liu, Lisheng and Pais, Prem and López-Jaramillo, Patricio and Leiter, Lawrence A and Dans, Antonio and Avezum, Alvaro and Piegas, Leopoldo S and Parkhomenko, Alexander and Keltai, Matyas and Keltai, Katalin and Sliwa, Karen and Peters, Ron J.G and Held, Claes and Chazova, Irina and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Sanchez-Vallejo, Gregorio and McKelvie, Robert and Pogue, Janice and Jung, Hyejung and Gao, Peggy and Diaz, Rafael and Lonn, Eva and HOPE-3 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | INTERHEART | MYOCARDIAL-INFARCTION | 52 COUNTRIES | CATARACT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - ethnology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Male | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Cholesterol | Hypertension | Myocardial infarction | Cerebral infarction | C-reactive protein | Diabetes mellitus | Cardiovascular disease | Lipids | Inflammation | Low density lipoprotein | Disease prevention | Surgery | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by Lonn, Eva M and Bosch, Jackie and López-Jaramillo, Patricio and Zhu, Jun and Liu, Lisheng and Pais, Prem and Diaz, Rafael and Xavier, Denis and Sliwa, Karen and Dans, Antonio and Avezum, Alvaro and Piegas, Leopoldo S and Keltai, Katalin and Keltai, Matyas and Chazova, Irina and Peters, Ron J.G and Held, Claes and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Parkhomenko, Alexander and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Leiter, Lawrence A and Molina, Dora I and McKelvie, Robert and Pogue, Janice and Wilkinson, Joanne and Jung, Hyejung and Dagenais, Gilles and Yusuf, Salim and HOPE-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2009 - 2020
In one comparison from a 2-by-2 factorial trial, over 12,000 participants with a mean baseline blood pressure of 138/82 mm Hg were assigned to candesartan plus... 
DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | RANDOMIZED-TRIALS | REDUCTION | REGIONS | PROSPECTIVELY-DESIGNED OVERVIEWS | HYPERTENSION | REGIMENS | Blood Pressure | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Hypotension - chemically induced | Antihypertensive Agents - adverse effects | Incidence | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Candesartan | Clinical trials | Dosage and administration | Cardiovascular diseases | Risk factors | Hypertension | Myocardial infarction | Cerebral infarction | Stroke | Risk groups | Cardiovascular disease | Hydrochlorothiazide | Cholesterol | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
by Yusuf, Salim and Lonn, Eva and Pais, Prem and Bosch, Jackie and López-Jaramillo, Patricio and Zhu, Jun and Xavier, Denis and Avezum, Alvaro and Leiter, Lawrence A and Piegas, Leopoldo S and Parkhomenko, Alexander and Keltai, Matyas and Keltai, Katalin and Sliwa, Karen and Chazova, Irina and Peters, Ron J.G and Held, Claes and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Accini, Jose L and McKelvie, Robert and Pogue, Janice and Jung, Hyejung and Liu, Lisheng and Diaz, Rafael and Dans, Antonio and Dagenais, Gilles and HOPE-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
by Eikelboom, John W and Connolly, Stuart J and Bosch, Jackie and Dagenais, Gilles R and Hart, Robert G and Shestakovska, Olga and Diaz, Rafael and Alings, Marco and Lonn, Eva M and Anand, Sonia S and Widimsky, Petr and Hori, Masatsugu and Avezum, Alvaro and Piegas, Leopoldo S and Branch, Kelley R.H and Probstfield, Jeffrey and Bhatt, Deepak L and Zhu, Jun and Liang, Yan and Maggioni, Aldo P and Lopez-Jaramillo, Patricio and O’Donnell, Martin and Kakkar, Ajay K and Fox, Keith A.A and Parkhomenko, Alexander N and Ertl, Georg and Störk, Stefan and Keltai, Matyas and Ryden, Lars and Pogosova, Nana and Dans, Antonio L and Lanas, Fernando and Commerford, Patrick J and Torp-Pedersen, Christian and Guzik, Tomek J and Verhamme, Peter B and Vinereanu, Dragos and Kim, Jae-Hyung and Tonkin, Andrew M and Lewis, Basil S and Felix, Camilo and Yusoff, Khalid and Steg, P. Gabriel and Metsarinne, Kaj P and Cook Bruns, Nancy and Misselwitz, Frank and Chen, Edmond and Leong, Darryl and Yusuf, Salim and COMPASS Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events... 
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights